FEATURES OF PIRIBEDIL USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENTS IN PATIENTS WITH CHRONIC HEART FAILURE
https://doi.org/10.20996/1819-6446-2014-10-4-406-410
Abstract
Aim. To study the features of piribedil use in the treatment of mild cognitive impairments in patients with chronic heart failure (CHF).
Material and methods. Open randomized study of piribedil efficacy in treatment of mild cognitive impairments of the patients with CHF and ischemic heart disease was performed. Eligible patients were randomized into group of piribedil treatment or control group. Each group included 20 patients. Patients of the main group received piribedil 50 mg a day during 12 weeks. Cognitive functions were estimated by Burdon’s test, 5 and 7 subtests of Wexler before and after 12 weeks of treatment.
Results. Significant improvement of cognitive tests was revealed in patients receiving piribedil at the final visit. Maximum effect of the drug was observed in younger patients, patients with increased carotid arteries intima-media thickness and increased left ventricular end-diastolic dimension.
Conclusion. Piribedil significantly improves memory and attention in patients with CHF and can be used in therapy of mild cognitive impairments in these patients.
About the Authors
N. S. Akimova
Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
T. V. Martinovich
Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
D. G. Persashvili
Clinical Hospital named after S.R. Mirotvortsev
Russian Federation
Bolshaya Sadovaya ul. 137 Saratov, 410054 Russia
Russian Federation
Bolshaya Sadovaya ul. 137 Saratov, 410054 Russia
Y. G. Shvarts
Saratov State Medical University named after V.I. Razumovsky
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
Russian Federation
Bolshaya Kazachia ul. 112, Saratov, 410012 Russia
References
1. Akimova N.S., Martynovich T.V., Mikhel N.D., Shvarc Ju.G. Clinical trial of the effect of Piribedil in the treatment of the mild cognitive impairements in patients with chronic heart failure which caused by ischemic heart disease. Fundamental Trials 2013; 9(4); 567-71. Russian (Акимова Н.С., Мартынович Т.В., Михель Н.Д., Шварц Ю.Г. Исследование эффективности пирибедила в лечении умеренных когнитивных расстройств у пациентов с хронической сердечной недостаточностью ишемического генеза. Фундаментальные Исследования 2013; 9 (4); 567-71).
2. Akimova N.S., Persashvili D.G., Martynovich T.V., Shvarc Ju.G. Cognitive impairements and condition of the gray matter of the brain in patients with chronic heart failure, caused by ischemic heart disease. Heart failure 2011; 5; 282-5. Russian (Акимова Н.С., Персашвили Д.Г., Мартынович Т.В., Шварц Ю.Г. Когнитивные расстройства и состояние серого вещества головного мозга при ХСН на фоне ИБС. Сердечная Недостаточность 2011; 5; 282-5).
3. Morozova T.E., Rykova S.M. Cardiovascular disease and cognitive disorders. Consilium medicum 2010; 9; 85-9. Russian (Морозова Т.Е., Рыкова С.М. Сердечно-сосудистые заболевания и когнитивные нарушения. Consilium medicum 2010; 9; 85-9).
4. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33; 1787-847.
5. Zaharov V.V. All-Russian program for research on the epidemiology and treatment of cognitive disorders in the elderly («Prometheus»). Neurologic Journal 2006; 3 (11); 27-32. Russian (Захаров В. В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический Журнал 2006;11 (3); 27-32.
6. Milchakova A.E., Popov G.R., Bykov A.V., Geht A.B. Clinical and pharmacoeconomic analysis of drug Piribedil (Pronoran) in the treatment of Parkinson's disease. Journal of neurology and psychiatry 2008; 4; 49-55. Russian (Мильчакова А.Е., Попов Г.Р., Быков А.В., Гехт А.Б. Клинико-фармакоэкономический анализ применения препарата пирибедил (Проноран) в лечении болезни Паркинсона. Журнал Неврологии и Психиатрии 2008; 4; 49-55).
7. Ostroumova O.D., Desnickaja I.V. Influence of the Rozuvastatinon on cognitive functiones. Consilium medicum 2007; 1(2); 61-3. Russian (Остроумова О.Д., Десницкая И.В. Влияние Розувастатина на когнитивные функции. Consilium medicum 2007; 1(2); 61-3).
8. Popova A.A., Alehina O.D., Burlachuk V.T. et al. The possibility of correction of mild cognitive disorders in elderly and old patients in General medical practice. Mental disorders in General medicine 2010; 2; 49-52. Russian (Попова А.А. Алехина О.Д. Бурлачук В.Т. и др. Возможности коррекции умеренных когнитивных расстройств у пациентов пожилого и старческого возраста в общемедицинской практике. Психические Расстройства в Общей Медицине 2010; 2; 49-52).
9. Parfenov VA, Starchina YA. Cognitive disorders in cerebrovascular diseases: diagnosis and treatment. Russian Journal of Medicine, 2008; (12): 1650-52. Russian (Парфенов В.А, Старчина Ю.А. Когнитивные расстройства при цереброваскулярных заболеваниях: диагноз и лечение. Русский медицинский журнал 2008;(12):1650-52).
10. Jahno N. N., Zaharov V. V,. Strachunskaja E.Ja. et al. Treatment of the nondemention cognitive impairements in patients with arterial hypertension and cerebral atherosclerosis (According to the Russian multicenter study evaluating the «FUJeTE »). Neurology Journal 2012; 4; 49-55. Russian (Яхно Н. Н., Захаров В. В., Страчунская Е. Я. и др. Лечение недементных когнитивных нарушений у пациентов с артериальной гипертензией и церебральным атеросклерозом (По данным Российского мультицентрового исследования «ФУЭТЕ»). Неврологический Журнал 2012; 4; 49-55).
11. Panza F, D'Introno A, Colacicco AM, et al. Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging. Dement Geriatr Cogn Disord 2008;25(4): 336-46.
12. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158(9); 1517-9.
13. Rybakova M.K., Alehin M.N., Mit'kov V.V. Practical guidelines of the ultrasound diagnostics. Echocardiography. Moscow: Vidar-M; 2008. Russian (Рыбакова М.К., Алехин М.Н., Митьков В.В. Практическое руководство по ультразвуковой диагностике. Эхокардиография. М.: Видар-М; 2008).
14. Karimov R.N., Shvarc Ju.G. Statistics for doctors, biologists and beyond... Part 2. How to study the connection. Saratov: SMU; 2009. Russian (Каримов Р.Н., Шварц Ю.Г. Статистика для врачей, биологов и не только… Часть 2. Как изучать связи. Саратов: СМУ; 2009).
15. Lee PH, Lim TS, Shin HW et al. Serum cholesterol levels and the risk of multiple system atrophy: a casecontrol study. Movement Disorders 2009; 15;24(5); 752-758.
16. Soran H, Hama S, Yadav R et al. HDL functionality. Curr Opin Lipidol 2012; 23(4); 353-66.
Review
For citations:
Akimova N.S., Martinovich T.V., Persashvili D.G., Shvarts Y.G. FEATURES OF PIRIBEDIL USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENTS IN PATIENTS WITH CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2014;10(4):406-410. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-4-406-410
Views:
906
Email this article 